Mark A Laughlin

US Patent:

6602885, Aug 5, 2003

Filed:

Nov 8, 2001

Appl. No.:

10/010481

Inventors:

Bahige M. Baroudy - Westfield NJ
John W. Clader - Cranford NJ
Hubert B. Josien - Jersey City NJ
Stuart W. McCombie - Caldwell NJ
Brian A. McKittrick - Bloomfield NJ
Michael W. Miller - Westfield NJ
Bernard R. Neustadt - West Orange NJ
Anandan Palani - Kenilworth NJ
Ruo Steensma - Weehawken NJ
Jayaram R. Tagat - Westfield NJ
Susan F. Vice - Mountainside NJ
Mark A. Laughlin - Edison NJ

Assignee:

Schering Corporation - Kenilworth NJ

International Classification:

A61K 314545

US Classification:

514316, 546186, 546187, 546188, 546191, 544542, 544336

Abstract:

The use of CCR5 antagonists of the formula or a pharmaceutically acceptable salt thereof, wherein R is optionally substituted phenyl, pyridyl, thiophenyl or naphthyl; R is H, alkyl or alkenyl; R is optionally substituted phenyl, phenylalkyl, heteroaryl or heteroarylalkyl, naphthyl, fluorenyl or diphenylmethyl; R is optionally substituted phenyl, heteroaryl or naphthyl; R is H, alkyl, fluoro-alkyl, cyclopropylmethyl, âCH CH OH, âCH CH âO-alkyl, âCH C(O)âO-alkyl, âCH C(O)NH , âCH C(O)âNHalkyl or âCH C(O)âN(alkyl) ; R is optionally substituted phenyl, heteroaryl or naphthyl, cycloalkyl, cycloalkylalkyl or alkoxyalkyl; and R , R , R , R and R are hydrogen or alkyl for the treatment of HIV, solid organ transplant rejection, graft v. host disease, arthritis, rheumatoid arthritis, inflammatory bowel disease, atopic dermatitis, psoriasis, asthma, allergies or multiple sclerosis is disclosed, as well as novel compounds, pharmaceutical compositions comprising them, and the combination of CCR5 antagonists of the invention in combination with antiviral agents useful in the treatment of HIV or agents useful in the treatment of inflammatory diseases.

US Patent:

6635646, Oct 21, 2003

Filed:

May 1, 2000

Appl. No.:

09/562729

Inventors:

Mark A. Laughlin - Edison NJ

Assignee:

Schering Corporation - Kenilworth NJ

International Classification:

A61K 3150

US Classification:

51425211, 51425218, 51425301, 51425311, 5142531, 51425309, 514340, 424 857

Abstract:

Methods for treating treatment-naive as well as treatment-experienced adult and pediatric patients having HIV-1 infections as well as patients co-infected with HIV-1 and HCV involving administering a therapeutically effective amount of pegylated interferon-alfa, e. g. , pegylated interferon alfa-2b, in association with a therapeutically effective amount of a CCR5 antagonist or preferably further in association with a therapeutically effective amount of at least one of ribavirin, IL-2, IL-12, pentafuside alone or in combination with a therapeutically effective amount of an anti-HIV-1 drug therapy, e. g. , HAART are disclosed.

US Patent:

6689765, Feb 10, 2004

Filed:

Jan 30, 2002

Appl. No.:

10/061011

Inventors:

Bahige M. Baroudy - Westfield NJ
John W. Clader - Cranford NJ
Hubert B. Josien - Jersey City NJ
Stuart W. McCombie - Caldwell NJ
Brian A. McKittrick - Bloomfield NJ
Michael W. Miller - Westfield NJ
Bernard R. Neustadt - West Orange NJ
Anandan Palani - Kenilworth NJ
Elizabeth M. Smith - Verona NJ
Ruo Steensma - Weehawken NJ
Jayaram R. Tagat - Westfield NJ
Susan F. Vice - Mountainside NJ
Mark A. Laughlin - Edison NJ
Eric Gilbert - Scotch Plains NJ
Marc A. Labroli - Mount Laurel NJ

Assignee:

Schering Corporation - Kenilworth NJ

International Classification:

A61K 31695

US Classification:

514 63, 514 64, 51425212, 51425213, 51425219, 51425301, 5142531, 51425311, 514 2, 514 42, 514 43, 514 45, 514 49, 514220, 514262, 514263

Abstract:

The use of CCR5 antagonists of the formula or a pharmaceutically acceptable salt thereof, wherein R is optionally substituted phenyl, pyridyl, thiophenyl or naphthyl; R is hydrogen or alkyl; R is substituted phenyl, substituted heteroaryl, naphthyl, fluorenyl, diphenylmethyl or optionally substituted phenyl- or heteroaryl-alkyl; R is hydrogen, alkyl, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, or optionally substituted phenyl, phenylalkyl, naphthyl, naphthylalkyl, heteroaryl or heteroarylalkyl; R , R and R are hydrogen or alkyl; R is hydrogen, alkyl or alkenyl; for the treatment of HIV, solid organ transplant rejection, graft v, host disease, arthritis, rheumatoid arthritis, inflammatory bowel disease, atopic dermatitis, psoriasis, asthma, allergies or multiple sclerosis is disclosed, as well as novel compounds, pharmaceutical compositions comprising them, and the combination of CCR5 antagonists of the invention in combination with antiviral agents useful in the treatment of HIV or agents useful in the treatment of inflammatory diseases.

US Patent:

7247631, Jul 24, 2007

Filed:

May 6, 2003

Appl. No.:

10/430370

Inventors:

Mark A. Laughlin - Edison NJ, US

Assignee:

Schering Corporation - Kenilworth NJ

International Classification:

A61K 31/50
A61K 31/501
A61K 31/497
A01N 43/40

US Classification:

51425201, 51425301, 5142531, 51425311, 51425309, 514340

Abstract:

Methods for treating treatment-naive as well as treatment-experienced adult and pediatric patients having HIV-1 infections as well as patients co-infected with HIV-1 and HCV involving administering a therapeutically effective amount of pegylated interferon-alfa, e. g. , pegylated interferon alfa-2, in association with a therapeutically effective amount of a CCR5 antagonist or preferably further in association with a therapeutically effective amount of at least one of ribavirin, IL-2, IL-12, pentafuside alone or in combination with a therapeutically effective amount of an anti-HIV-1 drug therapy, e. g. , HAART are disclosed.

US Patent:

7384944, Jun 10, 2008

Filed:

Sep 23, 2003

Appl. No.:

10/668862

Inventors:

Bahige M. Baroudy - Westfield NJ, US
John W. Clader - Cranford NJ, US
Hubert B. Josien - Jersey City NJ, US
Stuart W. McCombie - Caldwell NJ, US
Brian A. McKittrick - Bloomfield NJ, US
Michael W. Miller - Westfield NJ, US
Bernard R. Neustadt - West Orange NJ, US
Anandan Palani - Kenilworth NJ, US
Elizabeth M. Smith - Verona NJ, US
Ruo Steensma - Weehawken NJ, US
Jayaram R. Tagat - Westfield NJ, US
Susan F. Vice - Mountainside NJ, US
Mark A. Laughlin - Edison NJ, US
Eric Gilbert - Scotch Plains NJ, US
Marc A. Labroli - Mount Laurel NJ, US

Assignee:

Schering Corporation - Kenilworth NJ

International Classification:

A61K 31/497

US Classification:

51425214, 51425212, 51425213, 51425219, 51425301, 5142531, 51425311

Abstract:

The use of CCR5 antagonists of the formula.

US Patent:

8114879, Feb 14, 2012

Filed:

Mar 26, 2008

Appl. No.:

12/055900

Inventors:

Bahige M. Baroudy - Westfield NJ, US
John W. Clader - Cranford NJ, US
Hubert B. Josien - Jersey City NJ, US
Stuart W. McCombie - Caldwell NJ, US
Brian A. McKittrick - New Vernon NJ, US
Michael W. Miller - Scotch Plains NJ, US
Bernard R. Neustadt - West Orange NJ, US
Anandan Palani - Bridgewater NJ, US
Elizabeth M. Smith - Verona NJ, US
Ruo Steensma - Weehawken NJ, US
Jayaram R. Tagat - Westfield NJ, US
Susan F. Vice - Mountainside NJ, US
Mark A. Laughlin - Sandy UT, US
Eric Gilbert - Scotch Plains NJ, US
Marc A. Labroli - Morrestown NJ, US

Assignee:

Schering Corporation - Kenilworth NJ

International Classification:

A61K 31/497
C07D 403/00

US Classification:

51425218, 51425211, 51425214, 544295

Abstract:

The use of CCR5 antagonists of the formula.

US Patent:

20020004584, Jan 10, 2002

Filed:

Mar 8, 2001

Appl. No.:

09/801980

Inventors:

Mark Laughlin - Edison NJ, US

International Classification:

A61K038/21

US Classification:

530/351000, 424/085700

Abstract:

Methods for promoting an HIV-1 specific immune response in adult and pediatric patients having HIV-1 infections as well as patients co-infected with HIV-1 and HCV involving administering a therapeutically effective amount of pegylated interferon-alfa, e.g., pegylated interferon alfa-2b are disclosed.

US Patent:

20020182179, Dec 5, 2002

Filed:

Mar 1, 2000

Appl. No.:

09/516673

Inventors:

Mark Laughlin - Edison NJ, US
Paul Glue - Flemington NJ, US
Carlos Stalgis - Millington NJ, US

International Classification:

A61K038/21

US Classification:

424/085700

Abstract:

Methods for treating treatment-naive as well as treatment-experienced adult and pediatric patients having HIV-1 infections as well as patients co-infected with HIV-1 and HCV involving administering a therapeutically effective amount of pegylated interferon-alfa, e.g., pegylated interferon alfa-2b as monotherapy or preferably in association with a therapeutically effective amount of at least one of ribavirin, IL-2, IL-12, pentafuside alone or in combination with a therapeutically effective amount of an anti-HIV-1 drug therapy, e.g., HAART are disclosed.